Steve Hurly, LAVA Therapeutics CEO
Seagen tees up with Dutch I/O outfit, engineers $700M deal for EGFR asset
Amid reports that Merck was going to acquire Seagen, the Seattle company decided to do its own M&A — securing a back-heavy deal.
The antibody …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
